SCHEMBL7728624

SCHEMBL7728624

Cc1cc(C)cc(NC(=O)[C@@H](CCc2ccccc2)NC(=O)OC(C)(C)C)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 6/20 0.64
▸ CTSS P25774 6/20 0.64
▸ HDAC4 P56524 4/20 0.54
▸ HDAC1 Q13547 4/20 0.54
▸ HDAC8 Q9BY41 3/20 0.52
▸ HDAC3 O15379 2/20 0.52
▸ HDAC7 Q8WUI4 2/20 0.52
▸ HDAC2 Q92769 2/20 0.52
▸ HDAC10 Q969S8 2/20 0.52
▸ HDAC11 Q96DB2 2/20 0.52
▸ HDAC6 Q9UBN7 2/20 0.52
▸ HDAC9 Q9UKV0 2/20 0.52
▸ HDAC5 Q9UQL6 2/20 0.52
▸ CTSB P07858 2/20 0.49
▸ CTSL P07711 1/20 0.49
▸ SCN9A Q15858 1/20 0.48
▸ ACE P12821 1/20 0.47
▸ MMP2 P08253 1/20 0.47
▸ TACR1 P25103 1/20 0.46
▸ PPARA Q07869 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7722248 0.87 CTSK (0.62) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL12890034 0.85 CTSS (0.74) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL6550878 0.85 CTSS (0.74) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL13669553 0.85 CTSS (0.74) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL8695864 0.83 CTSK (0.63) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL4374188 0.82 CTSS (0.74) CTSKCTSSHDAC8CTSBCTSL
SCHEMBL4365866 0.82 CTSS (0.74) CTSKCTSSHDAC8CTSBCTSL
SCHEMBL18661099 0.82 CTSS (0.74) CTSKCTSSHDAC8CTSBCTSL
SCHEMBL7726821 0.81 CTSK (0.58) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL1979805 0.81 CTSS (0.72) CTSKCTSSCTSBCTSLSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 — — US disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 — — WO disclosed
Send feedback